BRAF and melanoma: The aim of targeted therapies is to inhibit the mitogen-activated protein kinase (MAPK) signaling pathway components, especially in cases of its constitutive activation due to the BRAF V600E mutation [9], which occurs in approximately 60% of melanomas [10].